Docetaxel and epirubicin supported by granulocyte colony-stimulating factor first-line in advanced breast cancer.
Polyzos A, Tsavaris N, Kosmas C, Gogas H, Vadiaka M, Markopoulos C, Giannopoulos A, Kalahanis N, Stamatiadis D, Kouraklis G, Karatzas G, Liapis C, Syrigos K.
Polyzos A, et al. Among authors: syrigos k.
Anticancer Res. 2003 May-Jun;23(3C):2917-23.
Anticancer Res. 2003.
PMID: 12926135
Clinical Trial.